Cardiometabolic reprogramming in pulmonary arterial hypertension:Implications for right ventricular dysfunction and therapeutic strategiesOA
Cardiometabolic reprogramming in pulmonary arterial hypertension:Implications for right ventricular dysfunction and therapeutic strategies
Guanghui Qian;Peng Zhang;Gaurav Choudhary;Hongwei Yao
Providence VA Medical Center,Providence 02908,USA||Department of Medicine,Warren Alpert Medical School of Brown University,Providence 02903,USAProvidence VA Medical Center,Providence 02908,USA||Department of Medicine,Warren Alpert Medical School of Brown University,Providence 02903,USAProvidence VA Medical Center,Providence 02908,USA||Department of Medicine,Warren Alpert Medical School of Brown University,Providence 02903,USAProvidence VA Medical Center,Providence 02908,USA||Department of Medicine,Warren Alpert Medical School of Brown University,Providence 02903,USA||Department of Molecular Biology,Cell Biology & Biochemistry,Division of Biology and Medicine,Brown University,Providence 02906,USA
metabolic modulatorsnatural productspulmonary arterial hypertensionRV fibrosisRV maladaptation
metabolic modulatorsnatural productspulmonary arterial hypertensionRV fibrosisRV maladaptation
《中草药（英文版）》 2026 (3)
515-527,13
This work was supported in part by the NIH grant R01HL166327,an Institutional Development Award(IDeA)from the NIGMS of NIH under grant P30GM149398.The views expressed in this article are those of the authors and do not reflect the posi-tion or policy of the Department of Veterans Affairs or the US Fed-eral Government.
评论